The PSG report said high discontinuation rates are now playing a major role in coverage decisions, as nearly two-thirds of patients without type 2 diabetes who take GLP-1s discontinue treatment within one year. In addition, 72% of those surveyed indicated that discontinuation rates and weight regain were at least moderately influential in their GLP-1 coverage decisions. Discontinuation rates are very high and employers want to know if this will actually provide a return on their investment if they (workers) arent taking them long-term, Lee said in an interview.
doi: 10.1007/s00125-025-06527-y 10
It acts on receptors in specic areas of the brain to efectively inhibit the appetite center, enhance satiety, andreduce food intake5
What is happening with these weight loss drugs is brand new, C
At this point, one of these scenarios will occur: Your Saxenda prescription will be covered
Each Atlas Lab vial ships with a complete Certificate of Analysis (COA): HPLC profile, mass spectrum, endotoxin tests, full batch traceability